Potential subscribers to Celera’s database might deal with Lothar Krinke, the company’s newest cheerleader. The newly installed vice president of business development and strategic planning works with online information as well as discovery and M&A efforts.
Though Krinke studied molecular biology, his experience is in business. He worked at consulting firms McKinsey and A.T. Kearney, focusing on biopharmaceuticals and R&D. “Then I turned 39,” he says, “and I thought, ‘I’ve been doing consulting for 10 years. It’s time for me to go back into the field.’”
That field was decidedly small. Krinke selected just three companies he would work for. “Celera was on top,” he says, declining to name the other two.
Leaving consulting was no light decision. “I have totally committed my personal fortune and energy to this company,” Krinke says, declining to elaborate. “There is not an option for me for this to fail.”
What drew Krinke was Celera’s high risk, high reward model — and he doesn’t seem to have doubts about his leap into genomics. “Whatever we do is going to be big,” he says. “I am convinced that this company is going to be unbelievably successful.”
— Meredith Salisbury